Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:37:08 EDT Fri 26 Jul 2024
Enter Symbol
or Name
USA
CA



Q:CAPR - CAPRICOR THERAPEUTICS INC - http://www.capricor.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CAPR - Q1.04.25·5.160.14.37-0.06-1.4275.71,1621,1454.45  4.56  4.328.2212  2.6819:54:45Jul 0115 min RT 2¢

Recent Trades - Last 10 of 1145
Time ETExPriceChangeVolume
19:54:45Q4.810.381
16:19:04Q4.440.011
16:13:51Q4.42-0.011
16:05:07Q4.43860.00861
16:03:59Q4.40-0.032,000
16:01:52Q4.37-0.061,705
16:01:46Q4.37-0.06375
16:00:01Q4.37-0.06100
16:00:01Q4.37-0.06818
16:00:01Q4.37-0.06229

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-07-01 09:00U:CAPRNews ReleaseCapricor Therapeutics Set to Join Russell 2000(TM) and Russell 3000(TM) Indexes
2024-06-28 09:00U:CAPRNews ReleaseCapricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
2024-06-25 10:31U:CAPRNews ReleaseCORRECTION: Capricor Therapeutics
2024-06-25 08:30U:CAPRNews ReleaseCapricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
2024-06-11 09:25U:CAPRNews ReleaseCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
2024-06-04 09:00U:CAPRNews ReleaseCapricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
2024-05-13 16:05U:CAPRNews ReleaseCapricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-05-09 09:15U:CAPRNews ReleaseCapricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
2024-05-08 09:00U:CAPRNews ReleaseCapricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
2024-05-06 09:00U:CAPRNews ReleaseCapricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
2024-04-24 09:00U:CAPRNews ReleaseCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
2024-03-21 08:30U:CAPRNews ReleaseCapricor Therapeutics to Present at Upcoming Investor Conferences
2024-03-06 08:30U:CAPRNews ReleaseCapricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
2024-02-29 16:05U:CAPRNews ReleaseCapricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-02-27 08:30U:CAPRNews ReleaseCapricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
2024-02-22 08:30U:CAPRNews ReleaseCapricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
2024-02-20 08:30U:CAPRNews ReleaseCapricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
2024-01-24 09:15U:CAPRNews ReleaseCapricor Therapeutics Announces Collaboration with the National Institutes of Health ‚  for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
2023-12-11 09:00U:CAPRNews ReleaseCapricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
2023-11-14 16:05U:CAPRNews ReleaseCapricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update